Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Moderna Inc., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Moderna Inc. debt to equity ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Moderna Inc. debt to equity ratio (including operating lease liability) improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Moderna Inc. debt to capital ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Moderna Inc. debt to capital ratio (including operating lease liability) improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Moderna Inc. debt to assets ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Moderna Inc. debt to assets ratio (including operating lease liability) deteriorated from Q3 2022 to Q4 2022 but then improved from Q4 2022 to Q1 2023 not reaching Q3 2022 level. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Moderna Inc. financial leverage ratio decreased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
Debt to Equity
Moderna Inc., debt to equity calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Financing lease liabilities, non-current | 831) | 912) | 922) | 641) | 646) | 599) | 238) | 328) | 138) | 110) | 109) | 68) | 39) | 39) | —) | —) | —) | ||||||
| Deferred lease obligation, non-current | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 14) | 11) | 11) | ||||||
| Lease financing obligation | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 34) | 34) | 33) | ||||||
| Total debt | 831) | 912) | 922) | 641) | 646) | 599) | 238) | 328) | 138) | 110) | 109) | 68) | 39) | 39) | 48) | 45) | 44) | ||||||
| Stockholders’ equity | 18,863) | 19,123) | 17,992) | 17,985) | 17,075) | 14,145) | 10,124) | 6,704) | 3,838) | 2,561) | 2,760) | 2,947) | 1,641) | 1,175) | 1,252) | 1,339) | 1,446) | ||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | 4.68 | 3.67 | 4.35 | 4.98 | 4.51 | 4.98 | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | — | — | — | — | ||||||
| Amgen Inc. | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | ||||||
| Bristol-Myers Squibb Co. | 1.19 | 1.27 | 1.20 | 1.29 | 1.42 | 1.24 | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | ||||||
| Eli Lilly & Co. | 1.69 | 1.52 | 1.58 | 1.97 | 1.77 | 1.88 | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | ||||||
| Gilead Sciences Inc. | 1.20 | 1.19 | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | ||||||
| Johnson & Johnson | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | ||||||
| Merck & Co. Inc. | 0.66 | 0.67 | 0.68 | 0.73 | 0.78 | 0.87 | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | ||||||
| Pfizer Inc. | 0.36 | 0.37 | 0.40 | 0.46 | 0.44 | 0.50 | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | ||||||
| Thermo Fisher Scientific Inc. | 0.83 | 0.78 | 0.67 | 0.72 | 0.81 | 0.85 | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | ||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 831 ÷ 18,863 = 0.04
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Moderna Inc. debt to equity ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
Debt to Equity (including Operating Lease Liability)
Moderna Inc., debt to equity (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity
= 927 ÷ 18,863 = 0.05
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Moderna Inc. debt to equity ratio (including operating lease liability) improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
Debt to Capital
Moderna Inc., debt to capital calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Financing lease liabilities, non-current | 831) | 912) | 922) | 641) | 646) | 599) | 238) | 328) | 138) | 110) | 109) | 68) | 39) | 39) | —) | —) | —) | ||||||
| Deferred lease obligation, non-current | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 14) | 11) | 11) | ||||||
| Lease financing obligation | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 34) | 34) | 33) | ||||||
| Total debt | 831) | 912) | 922) | 641) | 646) | 599) | 238) | 328) | 138) | 110) | 109) | 68) | 39) | 39) | 48) | 45) | 44) | ||||||
| Stockholders’ equity | 18,863) | 19,123) | 17,992) | 17,985) | 17,075) | 14,145) | 10,124) | 6,704) | 3,838) | 2,561) | 2,760) | 2,947) | 1,641) | 1,175) | 1,252) | 1,339) | 1,446) | ||||||
| Total capital | 19,694) | 20,035) | 18,914) | 18,626) | 17,721) | 14,744) | 10,362) | 7,032) | 3,976) | 2,671) | 2,868) | 3,015) | 1,680) | 1,213) | 1,299) | 1,383) | 1,490) | ||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | 0.04 | 0.05 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | 0.82 | 0.79 | 0.81 | 0.83 | 0.82 | 0.83 | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | ||||||
| Amgen Inc. | 0.92 | 0.91 | 0.91 | 0.94 | 0.98 | 0.83 | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | ||||||
| Bristol-Myers Squibb Co. | 0.54 | 0.56 | 0.54 | 0.56 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | ||||||
| Eli Lilly & Co. | 0.63 | 0.60 | 0.61 | 0.66 | 0.64 | 0.65 | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | ||||||
| Gilead Sciences Inc. | 0.55 | 0.54 | 0.54 | 0.56 | 0.57 | 0.56 | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | ||||||
| Johnson & Johnson | 0.43 | 0.34 | 0.30 | 0.30 | 0.31 | 0.31 | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | ||||||
| Merck & Co. Inc. | 0.40 | 0.40 | 0.41 | 0.42 | 0.44 | 0.46 | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | ||||||
| Pfizer Inc. | 0.26 | 0.27 | 0.28 | 0.32 | 0.31 | 0.33 | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | ||||||
| Thermo Fisher Scientific Inc. | 0.45 | 0.44 | 0.40 | 0.42 | 0.45 | 0.46 | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | ||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 831 ÷ 19,694 = 0.04
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Moderna Inc. debt to capital ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
Debt to Capital (including Operating Lease Liability)
Moderna Inc., debt to capital (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 927 ÷ 19,790 = 0.05
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Moderna Inc. debt to capital ratio (including operating lease liability) improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
Debt to Assets
Moderna Inc., debt to assets calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Financing lease liabilities, non-current | 831) | 912) | 922) | 641) | 646) | 599) | 238) | 328) | 138) | 110) | 109) | 68) | 39) | 39) | —) | —) | —) | ||||||
| Deferred lease obligation, non-current | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 14) | 11) | 11) | ||||||
| Lease financing obligation | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 34) | 34) | 33) | ||||||
| Total debt | 831) | 912) | 922) | 641) | 646) | 599) | 238) | 328) | 138) | 110) | 109) | 68) | 39) | 39) | 48) | 45) | 44) | ||||||
| Total assets | 24,125) | 25,858) | 26,056) | 26,043) | 27,609) | 24,669) | 20,923) | 16,153) | 12,694) | 7,337) | 4,651) | 3,486) | 2,068) | 1,589) | 1,591) | 1,685) | 1,806) | ||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | 0.46 | 0.46 | 0.49 | 0.51 | 0.51 | 0.52 | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | ||||||
| Amgen Inc. | 0.69 | 0.60 | 0.61 | 0.62 | 0.62 | 0.54 | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | ||||||
| Bristol-Myers Squibb Co. | 0.40 | 0.41 | 0.40 | 0.42 | 0.44 | 0.41 | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | ||||||
| Eli Lilly & Co. | 0.36 | 0.33 | 0.33 | 0.36 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | ||||||
| Gilead Sciences Inc. | 0.41 | 0.40 | 0.40 | 0.42 | 0.42 | 0.39 | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | ||||||
| Johnson & Johnson | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | ||||||
| Merck & Co. Inc. | 0.29 | 0.28 | 0.28 | 0.30 | 0.30 | 0.31 | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | ||||||
| Pfizer Inc. | 0.18 | 0.18 | 0.19 | 0.21 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | ||||||
| Thermo Fisher Scientific Inc. | 0.37 | 0.35 | 0.32 | 0.33 | 0.36 | 0.37 | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | ||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 831 ÷ 24,125 = 0.03
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Moderna Inc. debt to assets ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |
Debt to Assets (including Operating Lease Liability)
Moderna Inc., debt to assets (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 927 ÷ 24,125 = 0.04
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Moderna Inc. debt to assets ratio (including operating lease liability) deteriorated from Q3 2022 to Q4 2022 but then improved from Q4 2022 to Q1 2023 not reaching Q3 2022 level. |
Financial Leverage
Moderna Inc., financial leverage calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Total assets | 24,125) | 25,858) | 26,056) | 26,043) | 27,609) | 24,669) | 20,923) | 16,153) | 12,694) | 7,337) | 4,651) | 3,486) | 2,068) | 1,589) | 1,591) | 1,685) | 1,806) | ||||||
| Stockholders’ equity | 18,863) | 19,123) | 17,992) | 17,985) | 17,075) | 14,145) | 10,124) | 6,704) | 3,838) | 2,561) | 2,760) | 2,947) | 1,641) | 1,175) | 1,252) | 1,339) | 1,446) | ||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | 1.28 | 1.35 | 1.45 | 1.45 | 1.62 | 1.74 | 2.07 | 2.41 | 3.31 | 2.86 | 1.69 | 1.18 | 1.26 | 1.35 | 1.27 | 1.26 | 1.25 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | 10.14 | 8.04 | 8.84 | 9.77 | 8.80 | 9.51 | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | — | — | — | — | ||||||
| Amgen Inc. | 16.59 | 17.79 | 17.44 | 24.51 | 64.62 | 9.13 | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | ||||||
| Bristol-Myers Squibb Co. | 2.96 | 3.12 | 3.01 | 3.08 | 3.26 | 3.04 | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | ||||||
| Eli Lilly & Co. | 4.75 | 4.65 | 4.71 | 5.51 | 5.03 | 5.44 | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | ||||||
| Gilead Sciences Inc. | 2.95 | 2.97 | 2.97 | 3.11 | 3.17 | 3.23 | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | ||||||
| Johnson & Johnson | 2.77 | 2.44 | 2.35 | 2.33 | 2.39 | 2.46 | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | ||||||
| Merck & Co. Inc. | 2.30 | 2.37 | 2.41 | 2.48 | 2.61 | 2.77 | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | ||||||
| Pfizer Inc. | 1.94 | 2.06 | 2.10 | 2.24 | 2.23 | 2.35 | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.28 | 1.29 | 1.29 | 1.32 | 1.32 | 1.36 | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | ||||||
| Thermo Fisher Scientific Inc. | 2.24 | 2.21 | 2.08 | 2.14 | 2.26 | 2.33 | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | ||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 24,125 ÷ 18,863 = 1.28
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Moderna Inc. financial leverage ratio decreased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023. |